LINC01694: A Potential Drug Target and Biomarker (G105372840)

Target Name: LINC01694

NCBI ID: G105372840

LINC01694

Other Name(s): Long intergenic non-protein coding RNA 1694 | long intergenic non-protein coding RNA 1694

LINC01694: A Potential Drug Target and Biomarker

Long intergenic non-protein coding RNAs (lncNPCRs) have emerged as a promising class of genetic non-coding RNAs that can encode functional proteins or play a role in gene regulation. One of the most well-studied lncNPCRs is LINC01694, which has been shown to have important roles in various cellular processes, including cell growth, differentiation, and metabolism. As a result, LINC01694 has potential as a drug target and biomarker.

The discovery and characterization of LINC01694

LINC01694 was first identified as a unique lncNPCR in the human transcriptome using RNA sequencing (RNA-seq) data from the HGNC gene database. The RNA-seq data revealed that LINC01694 was expressed in various tissues and cells, including brain, heart, liver, and muscle, and at different stages of development. The expression level of LINC01694 was also highly correlated with the expression levels of several well-known protein genes, including Axial TOR, SIRT3, and HIPK3.

To further investigate the function of LINC01694, researchers used a variety of techniques, including RNA interference, overexpression, and co-expression analysis, to demonstrate that LINC01694 plays a role in regulating the expression of target genes. For example, RNA interference experiments revealed that LINC01694 can act as a negative regulator of the expression of the gene encoding the protein PDGF-BB, which is involved in cell growth and survival. Overexpression experiments demonstrated that LINC01694 can cause the expression of its target genes to be increased, such as the gene encoding the protein Pyknot, which is involved in the regulation of cell growth and the organization of tissues.

In addition to its role in regulating gene expression, LINC01694 has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion. For example, RNA-seq analysis of LINC01694-containing cells revealed that LINC01694 was highly expressed in cells that were able to invade a Matrigel matrix, indicating that it may be involved in the regulation of cell movement and invasion.

The potential utility of LINC01694 as a drug target

The potential utility of LINC01694 as a drug target is based on its ability to regulate the expression of target genes and its role in various cellular processes. LINC01694 has been shown to play a role in the regulation of cell growth, differentiation, and metabolism, which are all key processes that are involved in the development and treatment of many diseases.

One potential target for LINC01694 is the protein PDGF-BB, which is involved in cell growth and survival. The over-expression of PDGF-BB has been shown to promote the growth and survival of cancer cells, and is a potential cause of cancer. LINC01694 has also been shown to regulate the expression of the PDGF-BB gene, which suggests that it may play a role in the regulation of PDGF-BB expression and its effects on cell growth and survival.

Another potential target for LINC01694 is the gene encoding the protein Pyknot, which is involved in the regulation of cell growth and the organization of tissues. The over-expression of Pyknot has been shown to promote the growth and survival of cancer cells, and is a potential cause of cancer. LINC01694 has also been shown to regulate the expression of Pyknot, which suggests that it may play a role in the regulation of Pyknot

Protein Name: Long Intergenic Non-protein Coding RNA 1694

The "LINC01694 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01694 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets